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when primary PCI is not possible within recommended door to
balloon time. Our objective was to conclude the efﬁcacy and safety
of tenecteplase in patients with STEMI.
Method: Data of 500 patients with STEMI who received tenecte-
plase in the last 1 year were analyzed.
Result: 90% patients had successful thrombolysis (SUCC.TH).
Hypertensives, diabetics, smokers and dyslipidemic patients had
SUCC.TH rates comparable to the general patient data. SUCC.TH
rates were signiﬁcantly lower in the elderly patients (>70 years,
86%, p < 0.0001), patients with history of IHD (88%, p < 0.0004) and
in patients receiving tenecteplase >6 h after onset of chest pain
(80%, p < 0.0001). SUCC.THwas signiﬁcantly higher in patientswho
received early thrombolysis (<3 h after onset of chest pain, 89%,
p = 0.006). Overall mortality was 1.5%. It was signiﬁcantly higher in
the elderly (4.5%), patients with history of IHD (3%), females (3%),
with delayed thrombolysis (5%). Overall incidence of ICH 0.3%,
other bleeds 2%, stroke 0.1% and ventricular tachyarrhythmias
2.5%were noted. Age>70 years, diabetes, dyslipidemia and history
of IHD were associated with a higher incidence of heart failure, re
infarction or ventricular tachyarrhythmias. Incidence of ICH and
other bleeds were comparable amongst all patient subgroups.
Ventricular arrhythmias were signiﬁcantly higher in dyslipi-
demics, with history of IHD, Killip class III & IV.
Conclusion: The study conﬁrmed the safety and efﬁcacy of tenec-
teplase.
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Background: Diabetes has been an Achilles heel of patients with
limus eluting drug-eluting stents (DES). In SPIRIT sub studies PES
had equivalent or better results than EES in Insulin requiring
diabetics. Our objective was to analyze this factor in Tuxedo-India
study, the largest ever DES study in patients with diabetesmellitus
comparing PES with EES.
Method: TUXEDO is a prospective, randomized, multicentre clin-
ical trial in patients with DM comparing the safety and efﬁcacy
outcomes of a PES with EES in a non-inferiority trial design.
We randomly assigned 1830 patients with diabetes mellitus to
receive either PES (TAXUS ElementTM) or EES (XIENCE PrimeTM)
in a non-inferiority trial design. Of these patients, 747 (40%) were
insulin requiring diabetics; 365/914 (39.9%) in PES group and
382/916 (41.7%) in the EES group. In a subset analyses, we evaluated
the 1-year rates of target-vessel failure (TVF), myocardial infarc-
tion (MI), stent thrombosis (ST), target-lesion revascularization
(TLR), and target-vessel revascularization (TVR) with PES or EES
in insulin requiring diabetics.
Results: The baseline characteristics of PES and EES groups in
insulin requiring diabetics were comparable. In insulin requiring
patients, there was a statistically signiﬁcant higher 1-year rate of
TVF in the PES group as compared to the EES group (7.9% vs. 3.4%,
p = 0.006). In addition, the rate of MI (4.4% vs. 1.3%, p = 0.01), ST
(3.0% vs. 0.5%, p = 0.009), TLR (5.2% vs. 1.0%; p = 0.001) andTVR (5.2%
vs. 1.0%; p = 0.001) was signiﬁcantly higher in the PES group com-
pared to the EES group over 1-year follow-up period.
Conclusion: PES, as compared to EES had higher rates of TVF,
MI, ST, TVR, and TLR at 1-year follow-up. The superiority of
EES, as compared to PES was maintained in insulin requiring
diabetics.
Paclitaxel-eluting versus everolimus-
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Background: Prior trials (such as the SPIRIT trials) have shown the
superiority of EES over PES in general cohort. However, subgroup
analyses from these trials have failed to consistently show a
superiority of EES over PES in the diabetic cohort, leading to the
general notion that a 'taxol' eluting stent (such as PES) works as
well as a limus eluting stent (such as EES) in subjects with DM. Our
objective was to conduct a sufﬁciently powered randomized trial
comparing the efﬁcacy and safety of PESwith EES in a population of
patients with DM on drug treatment.
Method: TUXEDO is a prospective, randomized, multicenter clin-
ical trial in patients with DM comparing the safety and efﬁcacy
outcomes of a PES with EES in a non-inferiority trial design.
We randomly assigned a total of 1830 patients with DM, at 46
centers in India to receive either PES (TAXUS ElementTM Boston
scientiﬁc) or EES (Xience PrimeTM Abbott Vascular) without a
routine angiographic follow up. The primary endpoint was target
vessel failure deﬁned as a composite of cardiac death, target vessel
myocardial infarction or ischemia driven target vessel revascular-
ization at 12 months follow up.
Results: The mean age of the patients included was 58.4 years,
males 75.3% with the mean duration of DM being 6.5 years. Insulin
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requiring diabetics were 40.8% of the population studied. ACS was
the presentation in 52.3% patients.
Primary endpoint results will be presented.
Conclusion:TUXEDO is the largest randomized trial of PES vs EES in
subjectswithDMandwill provide additional insights intomanage-
ment of these high risk patients.
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Background: Coronary artery disease is currently the most com-
mon, non-infectious disease in India. STEMI is the most cata-
strophic presentation. Primary PCI is the preferred reperfusion
strategy in patients with STEMI presenting within 12 h to an
experienced center. There is paucity of data regarding primary
PCI in ourmilieu. This study is designed to prospectively look at the
various aspects of contemporary practice of primary PCI at a
tertiary care hospital and also to evaluate the 30-day outcomes.
Methods: All patients who present to emergency room as STEMI
within 12 h of symptom onset and give informed consent for
primary PCI as the reperfusion therapy are being enrolled for this
study. The detailed demographic data is being collected system-
atically. In addition the ECG and echocardiographic ﬁndings the
angiographic ﬁndings and procedural details are reviewed by an
independent investigator. Procedural success is deﬁned as
achievement of vessel patency to a residual stenosis <30%. The
patients are being followed during their in-hospital stay for any
acute complications and at 30 days for occurrence ofmajor adverse
cardiac events (all cause mortality, acute and sub acute stent
thrombosis as per ARC deﬁnition, target lesion revascularization,
and major bleeding as per BARC criteria). The 30 day follow up
results are being recorded.
Results: In this ongoing study 56 patients, 51(89.7%) males, mean
age 59.3 years. 46 (81.4%) patients presented as Killip class I, 6
(11.1%) as Killip class II and 2 (3.7%) as Killip III and IV each. 32
(58.6%) patients had inferior while 21 (38.2%) had anterior wall MI
at presentation. The mean time to hospital arrival from symptom
onset was 3.4 h and mean door to balloon time was 59.9 min. On
angiography 20 (37.03%) had single vessel disease while 22 (40.7%)
and 10 (18.5%) had double and triple vessel disease respectively. All
patients were loaded with aspirin 325 mg. The second antiplatelet
agent was the clopidogrel in 16.6% cases and ticagrelor in 66.6%
cases, given in emergency room, while prasugrel was given in
16.6% cases in cath lab after conﬁrmation of coronary anatomy.
Heparin alone was used in 12 (21.4%) cases, bivalirudin in 6 (10.7%)
and heparin + GpIIb/IIIa inhibitors were used in 38 (67.8%) patients
and the most common agent being abciximab (61.6% cases).
Thrombus aspiration was done in 27 (48.1%) patients. All patients
were treated with DES except one patient in which bioresorbable
scaffold (Absorb) was deployed. Culprit vessel revascularization
was the default strategy in majority (81%). In 5 cases multivessel
revascularization was done, out of which it was done during the
index procedure in 3 patients and as a staged procedure in 2
patients. There was one in-hospital death due to no reﬂow phe-
nomenon during index procedure. At 30 days 2 patients died, one
with sepsis and multiorgan failure and other had sudden death at
home without establishing the cause and included as probable
stent thrombosis. Bleeding complications included BARC subtype 1
in 13%, and type 2 in 3.4% patients. No major bleeding, BARC
subtype 3, was recorded at 30 days follow up. All the bleeding
complications were occurred in those patients, who received
heparin + Gp IIb/IIIa inhibitor.
Conclusions:This ongoing study throws light on important aspects
of the clinical and procedural proﬁle of patients presenting with
STEMIwho are undergoing primary PCI. Data of 100 patientswill be
presented.
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Background: Cardiovascular diseases (CAD) are the leading cause
of morbidity and mortality in patients of CKD and they begin well
before the onset of dialysis. Optimal approach of revascularization
in patients with kidney disease has not been determined.With the
availability of drug eluting stents & DAP, the scenario has changed.
The objective of study was to see disease pattern, immediate and
short term outcome of CAD in patients having CKD, with PCI.
Methods: We included 305 patients of CKD (with creatinine clear-
ance <60 ml/min/1.73 m2 having CAD, who underwent PCI with
DES (study group) and compared with similar number of age and
sex matched controls with creatinine clearance ≥60 ml/min/
1.73 m2, having CAD who underwent PCI with DES (control group).
The clinical and angiographic follow-up data before and after PCI
was collected at 1 month, 6 months and 12 months, using a
standard questionnaire. Data about amount of dye used, type of
dye used, renal outcomes at discharge, type of antiplatelet used,
beta blockers, ACE inhibitors/ARB, statins used & Duration of stay
in hospital was collected. Using amultiple logistic regressionmode
multivariable analysis was performed.
Results: The base line variables were similar in the 2 groups. There
was a gradual increase of prevalence of HTN as creatinine clear-
ance falls. More number of patients in study group had diabetes as
compared to control group but the difference between two groups
was not statistically signiﬁcant. There was no signiﬁcant differ-
ence between two groups regarding smoking and dyslipidemia.
Height was not signiﬁcantly different between two groups; how-
ever weight & BMI was signiﬁcantly lower in study group. Ejection
fraction was signiﬁcantly lower in study group as compared to
control group ( p < .001). Mean ejection fraction was 47.39% in
study group; it was 51.67% in control group. Hemoglobin, BUN,
serum creatinine & mean eGFR were signiﬁcantly lower in study
group. To estimate creatinine clearance EPI-CKD equation was
used.
Unstable angina as indication for PCI was signiﬁcantly more in
study group. In study group more patients had triple vessel dis-
ease, more lesions was of diffuse & calciﬁed type ( p < .001). Type B
lesionsweremore in control group and type C lesionsweremore in
study group ( p < .001). Angiotensin converting enzyme inhibitors
or angiotensin receptor blockers were used less in study group as
compared to control group. Amount of dye used during PCI was
higher in control group. Iodixanol (iso-osmolar) was used more in
study group. More number of patients in study group developed
contrast induced nephropathy. Rate of complete revascularization
achieved was also less in lower creatinine clearance group
( p < .001). Average number of days stayed in hospital was signiﬁ-
cantly more in study group ( p < .001). Peri-procedural MI occurred
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